All episodes

In this episode, experts in diabetes and virology, Profs. Knut Dahl-Jørgensen (University of Oslo), Heikki A. Hyöty (Tampere University), and Decio L. Eizirik (Université Libre de Bruxelles), explore the long-debated link between viral infections and type 1 diabetes. With new technologies enabling the detection of viruses at unprecedented sensitivity, the evidence connecting enteroviruses - particularly Coxsackie B viruses - to beta cell damage is becoming stronger.

The discussion covers groundbreaking studies detecting viruses in pancreatic tissue, trials using antiviral therapies to preserve insulin production, and the development of vaccines aimed at preventing disease onset. The panel also explores why certain...

In this episode, members of the EASD Global Council, Dr. Fawaz Alzaid and Dr. Banshi Saboo, share their perspectives on the global challenges of diabetes, highlighting how regional differences shape both risk and care. From the Middle East to South Asia, they explore how factors such as climate, diet, and socioeconomic conditions influence diabetes prevalence and outcomes.

The discussion delves into unique population-specific characteristics, including the “thin-fat” phenotype seen in India, the impact of extreme heat on physical activity in the Middle East, and the role of high-carbohydrate diets across Asia. The speakers also reflect on the importance of global...

In this episode, leading experts Dr. Daniela Liśkiewicz and Dr. Juan Pablo Frías explore the rapidly evolving landscape of anti-obesity medications.

From the rise of GLP-1-based therapies and oral treatments to next-generation multi-agonists, this discussion highlights how innovation is transforming obesity care. The conversation moves beyond weight loss alone, focusing on treatment quality, long-term weight maintenance, and patient-centred outcomes.

The speakers also examine emerging therapeutic targets, the importance of preserving muscle mass, and the growing role of lifestyle interventions alongside pharmacotherapy. Looking ahead, they share insights into future directions, from resetting metabolic “set points” to improving global access to treatment....

In this episode, leading experts Maciej T. Małecki, Norbert Hermanns and Dominic Ehrmann explore the essential role of clinical psychology in diabetes care.

Living with diabetes, particularly type 1 diabetes, requires constant decision-making and places a significant psychological burden on individuals and their families. From diabetes distress and depression to fear of hypoglycaemia, mental health challenges can directly impact glycaemic control and quality of life.

This discussion highlights why clinical psychologists must be integrated into multidisciplinary diabetes teams, the need for specialised “diabetes psychologists,” and how education, guidelines and policy change can help address current gaps in care.

In this episode, we explore the rapidly evolving world of scientific publishing and the challenges facing researchers today, featuring insights from Diabetologia Editor in Chief Prof. Hindrik Mulder, Maria Hodges, Past EASD Early Career Member Pierre Larraufie and Annette Schürmann.

From the rise of predatory journals and paper mills to the growing influence of artificial intelligence, the landscape is becoming increasingly complex.

Our experts discuss how open access has reshaped publishing, why peer review remains essential, and the pressures placed on early career researchers navigating where and how to publish. They also explore the limitations of impact factors, the risks...

In this episode, Prof. Chantal Mathieu and Prof. Francesco Dotta discuss two major European clinical trials presented at the EASD Annual Meeting: MELD-ATG and VERA-T1D.

Both studies were conducted through the INNODIA consortium, a large European collaboration aimed at identifying biomarkers and testing new disease-modifying therapies for type 1 diabetes.

The VERA-T1D trial investigated verapamil, a long-established cardiovascular drug, for its potential to preserve beta cell function after diagnosis. While the study narrowly missed its primary endpoint, the results provide important insights into disease heterogeneity and future combination therapies.

The MELD-ATG trial used an innovative adaptive trial design to identify...

In this episode, members of the EASD Committee on Clinical Affairs (CCA) discuss how clinical guidance is developed, reviewed and translated into real-world practice. CCA Chair, Prof. Richard Holt and Prof. Anne Peters explore the production of consensus reports, expert opinion documents and the EASD’s new guideline programme.

They discuss the first EASD guideline on diabetes distress, the upcoming guideline on continuous glucose monitoring in type 2 diabetes, and updates to the Type 1 diabetes consensus report. The conversation also highlights the critical role of patient involvement, public consultation and policy engagement in ensuring that guidance improves care across Europe...

In this episode, Prof. Nita Forouhi (University of Cambridge) and Prof. Michael Lean (University of Glasgow) explore the science behind nutrition, weight loss and type 2 diabetes remission. They discuss the role of ultra-processed foods, meat consumption and the importance of whole-food, minimally processed diets.

The conversation highlights groundbreaking research showing that substantial, intentional weight loss can reverse type 2 diabetes by reducing fat in organs like the liver, pancreas, and heart, restoring insulin sensitivity and pancreatic function.

They also tackle how to communicate evidence-based messages amid a flood of misinformation, and the importance of patient-centred research and guidance for...

In this episode, experts from the University of Amsterdam (Prof. J. Hans de Vries), the University of Newcastle (Prof. James A.M. Shaw) and Deakin University (Prof. Jane Speight) explore one of the most feared complications of type 1 diabetes: severe hypoglycaemia.

While advances in continuous glucose monitoring and automated insulin delivery have reduced severe episodes by around 40%, they have not eliminated the problem. The discussion examines why technology has limits, the challenges of impaired awareness and when transplantation may be considered for people with recurrent severe hypoglycaemia.

The conversation also highlights the profound psychological burden of hypoglycaemia; from trauma...

In this episode, Prof. Gill Livingston (University College London) and Prof. Thomas van Sloten (UMC Utrecht) explore the complex relationship between diabetes and dementia. People with diabetes face a higher risk of cognitive decline, particularly those with type 2 diabetes, and as treatment improves and life expectancy increases, dementia is becoming a growing clinical challenge.

The discussion examines how diabetes medications, including GLP-1 receptor agonists and SGLT2 inhibitors, may influence cognitive outcomes, the role of lifestyle and vascular risk factors, and why prevention must become central to diabetes care.

This episode also highlights the urgent need for clinical trials that...